Compare Becton Dickinson and Co (BDX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Procter & Gamble Co — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Procter & Gamble Co trades at $145.19 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 7× Becton Dickinson and Co's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| BDX | PG | |
|---|---|---|
Market Cap | $48.93B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $167.18 |
52-Week Low | $138.62 | $138.10 |
Enterprise Value | $65.03B | $366.23B |
Dividend Yield | 2.34% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and a strong net margin of 18.44%. Recent earnings have consistently beaten expectations, and a dividend of $1.09 per share is scheduled for payment in August 2026. Analyst consensus is bullish with a price target of $161.20, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
PG offers stability with consistent earnings beats and a reliable dividend, but premium valuations and soft demand outlook pose near-term risks. Supply chain improvements and brand partnerships provide growth catalysts, while economic sensitivity and competitive pressures remain headwinds. The stock presents a balanced opportunity for income-focused investors seeking defensive exposure amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
